+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 178 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether the video-based exercise program Bliib fit - mach mit can improve physical fitness in older adults living in residential care facilities. The study aims to see if this program enhances physical fitness, quality of life, perceived fall risk, self-efficacy, and daily physical activity levels. This trial compares the video-based program to a caregiver-led activation program as an optimized standard care approach. Participants will take part in either the video-based exercise program or the caregiver-led activation program for 12 weeks. Each participant will engage in sessions four times a week, with each session lasting about 20 minutes. The video-based program focuses on mobilization, muscle strengthening, coordination, balance, and relaxation, supervised by a care professional. The caregiver-led activation program is instructed and carried out by care professionals individually or in groups. During the study, researchers will assess participants at baseline, after 12 weeks of intervention, and again 12 weeks after the intervention ends. They will measure physical fitness through tests like the Short Physical Performance Battery, grip strength, and a 2-minute walking test. Secondary measures include health-related quality of life, falls efficacy, self-efficacy, and physical activity tracked with accelerometers. This comprehensive monitoring aims to understand how the programs affect participants over time.

All AgesAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Healthy Volunteer

Researchers are working to create and use a comprehensive database focused on intracranial aneurysms IA. This project collects and studies clinical history, imaging data, biological samples, and other information to understand factors linked to the formation and rupture of aneurysms. They aim to identify genetic, environmental, and anatomical markers, as well as evaluate outcomes from different treatment strategies and improve patient care protocols. Participants include patients with diagnosed aneurysms, both ruptured and unruptured, family members of affected individuals, and healthy volunteers. Data collected involves detailed clinical records, imaging scans like MRI angiography and CT angiography, and various biological samples such as blood, cerebrospinal fluid, saliva, and stool. Consent covers access to medical records, use of biological samples, and potential future research uses including genetic analyses. During the study, participants provide health and lifestyle information, imaging data, and biological samples. Researchers will monitor multiple long-term outcomes including disease progression, life expectancy, quality of life, neurological and cognitive status, and treatment effects over periods up to 20 years. Data confidentiality is maintained, and participants can withdraw at any time without affecting their medical care. The study aims to validate disease models and support advances in aneurysm management and research.

Age: 18Years +All Genders
22 locations
S

Actively Recruiting

Researchers are evaluating treatments for high-grade serous and certain other types of ovarian cancer that tend to grow and spread quickly. This study focuses on advanced cancers that started in the ovaries, lining of the belly, or fallopian tubes. The trial aims to assess the safety, tolerability, and response of a study drug called Raludotatug Deruxtecan R-DXd, which is an antibody drug conjugate designed to target and destroy cancer cells. This research includes a dose escalation phase followed by an expansion phase using the recommended dose. Participants will receive R-DXd through intravenous infusions every three weeks, often combined with other anticancer treatments such as carboplatin, paclitaxel, bevacizumab, pembrolizumab, or MK-2010. These combinations vary across different groups in the study, with some receiving up to six cycles of chemotherapy drugs over approximately four months, and others receiving immunotherapy or targeted therapy for longer periods, up to two years. The study allows continued treatment with R-DXd until disease progression or discontinuation. During the trial, participants will undergo regular clinical assessments including imaging scans to measure tumor response, monitoring for side effects, and laboratory tests. The main outcomes include tracking dose-limiting toxicities, adverse events, treatment discontinuations due to side effects, objective tumor response, and progression-free survival. Follow-up may continue for up to several years to evaluate longer-term effects and survival. The total duration of participation depends on treatment response and tolerability.

Age: 18Years +FEMALEPhase 1Phase 2
40 locations
S

Actively Recruiting

Researchers are investigating new treatments for certain advanced solid tumors, which are cancers found mostly in organs and tissues rather than in blood or fluids. These tumors may have spread or returned after previous treatments and may not be treatable with surgery or radiation. The study focuses on evaluating MK-2010 combined with sacituzumab tirumotecan sac-TMT, an antibody-drug conjugate designed to target and destroy cancer cells. The trial aims to assess the safety and tolerability of this combination and observe how many participants experience tumor shrinkage or disappearance. Participants receive MK-2010 and sac-TMT through intravenous infusions. The trial includes two parts a safety lead-in cohort and signal-finding cohorts using the dose determined in the first part. Premedications such as histamine receptor antagonists, acetaminophen, and dexamethasone are given according to approved guidelines to manage potential side effects. Emergency medications like epinephrine are also available as needed. Throughout the study, participants undergo regular evaluations to monitor safety, side effects, and treatment responses, including adverse events and dose-limiting toxicities. Outcome measures include the objective response rate and duration of response over several years. Drug levels and immune responses are also assessed periodically. The trial spans several years, with ongoing monitoring to understand the treatments impact and tolerability.

Age: 18Years +All GendersPhase 2
4 locations
P

Actively Recruiting

Researchers are studying MK-7262, a trial medicine designed to lower Lipoproteina Lpa levels in the blood. The study aims to learn about the effects of MK-7262 alone and in combination with another trial medicine called enlicitide, which belongs to a group of medicines that lower low-density lipoprotein cholesterol LDL-C. This Phase 2 clinical trial evaluates the ability of these medicines to reduce Lpa and LDL-C levels and assesses their safety and tolerability. Participants will be randomly assigned to one of four groups MK-7262 with enlicitide, MK-7262 alone, enlicitide alone, or placebo for both medicines. All treatments are given orally once daily for up to approximately 12 weeks. The study is double-blind with placebo controls, and the medicines are taken as coated tablets. The trial monitors effects at specific time points including weeks 8 and 12. During the trial, participants will undergo blood tests to measure changes in Lpa and LDL-C levels from baseline. Researchers will track adverse events and monitor safety for up to about 20 weeks. The primary outcomes include percent changes in Lpa and LDL-C at week 8 and the number of participants experiencing side effects or discontinuing treatment due to side effects. Participation lasts for the treatment period and follow-up assessments.

Age: 18Years +All GendersPhase 2
76 locations
P

Actively Recruiting

Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
193 locations
S

Actively Recruiting

Researchers are evaluating whether an individualized physiotherapy program tailored to each persons specific motor deficits can better support physical function compared to usual care physiotherapy in people with Amyotrophic Lateral Sclerosis ALS. This study uses diagnostic assessments with a robotic leg press system to identify muscle function strengths and weaknesses. The aim is to develop safer and more patient-centered physiotherapy strategies for ALS patients. Participants are assigned either to an individualized physiotherapy program or to continue with the usual care physiotherapy. About two-thirds of participants receive the tailored program based on their specific functional deficits, while one-third continue standard therapy following typical clinical practice. The study follows participants over a period of 12 months. Throughout the study, participants will engage in physiotherapy sessions approximately three to five times per week, each lasting about 30 minutes. Researchers will assess physical function using tools like the ALS Functional Rating Scale-Revised ALSFRS-R, focusing on activities such as climbing stairs at six months. The study monitors progress and outcomes to understand how different physiotherapy approaches impact ALS motor function and quality of life.

All AgesAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how different doses of a study medicine called Inno8 work in the bodies of people with haemophilia A. The purpose is to see if Inno8 is safe for use in this condition. This is a phase 1 treatment study sponsored by Novo Nordisk AS, lasting about 11 weeks, involving adult males with haemophilia A. Participants will receive oral doses of the study drug NNC0442-0344 A across three experimental cohorts. The dosing will be monitored closely throughout the study period. The study is designed as a single-group, non-randomized trial without blinding. During the study, participants will be evaluated for side effects and blood markers related to coagulation, such as D-dimer, prothrombin fragments, fibrinogen, and platelets. Researchers will also measure drug concentration levels and immune response indicators from the first dose through to the end of follow-up at Day 46. Safety assessments will be ongoing to monitor adverse events during the treatment and follow-up period.

Age: 18Years - 64YearsMALEPhase 1
33 locations
E

Actively Recruiting

This research aims to compare two surgical approaches for patients experiencing increased intracranial pressure caused by malignant stroke. It investigates whether using a single surgery with an individually molded space-expanding shield can be a viable alternative to the standard decompressive hemicraniectomy followed by a second surgery called cranioplasty. The study is planned as a randomized, controlled, multicenter trial to evaluate these methods in stroke patients aged 18 to under 70. Participants will be randomly assigned to one of two groups. The experimental group will receive decompressive hemicraniectomy with implantation of a space-expanding shield that allows brain swelling while providing protection in a single surgery. The control group will undergo the standard decompressive hemicraniectomy without the shield and later undergo cranioplasty about 90 days after the initial surgery. Follow-up examinations are scheduled at 1 to 7 days, 6 weeks, 3 months, and 6 months after surgery. During the study, participants will undergo evaluations including neurological assessments and imaging to monitor recovery and complications. Researchers will measure outcomes such as the modified Rankin Scale score at 6 months, number of additional surgeries for intracranial pressure control, infections, wound healing, syndrome of the trephined, survival, cosmetic satisfaction, and quality of life. The total duration of participation for each patient is 6 months, with safety and recovery closely monitored throughout.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
6 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations

1-10 of 178

1